Merck CEO Details $1 Billion US Biologics Facility and Job Creation

New Biologics Manufacturing Facility

• 🏭 Merck is constructing a new $1 billion, state-of-the-art biologics manufacturing facility in Wilmington, Delaware.
• 🎯 The facility will have the capability to produce both drug substance and drug product, with the intent to make it the primary site for the oncology drug Keytruda.
• 🇺🇸 This investment is part of a strategy to source US-made drugs for US patients, building on over $12 billion already invested since 2018.

Job Creation and Economic Impact

• 💼 The initial $1 billion investment will create 500 full-time positions and employ 4,000 construction workers.
• 📈 The site has potential for expansion up to $5 billion, which could lead to a workforce of 2,000 employees and nearly 30,000 construction jobs over time.
• 💰 These will be high-paying jobs benefiting tradesmen and manufacturing sectors in the United States.

Impact of Tax Policy

• 🏛️ Favorable tax policy, specifically the Tax Cuts and Jobs Act of 2018, was a catalyst for Merck's decision to bring back cash and invest in the US.
• 💡 The CEO emphasizes that favorable tax policy matters and is something Merck supports.

Future Pipeline and Keytruda's Evolution

• 🚀 While Keytruda is a significant franchise, Merck is preparing for its patent expiration in 2028 by investing in a subcutaneous form and next-generation therapies.
• 🌟 The company anticipates launching over 20 new products in the next 3-5 years, projecting over $50 billion in potential revenue by the mid-2030s.
• 🧬 Merck is diversifying its portfolio into areas like immunology, cardiometabolics, and developing new vaccines and an oral PCSK9 for arterial sclerosis.

Addressing Pharmaceutical Pricing and Tariffs

• 📉 Merck aims to reduce out-of-pocket costs for patients by addressing the middleman's share of pharmaceutical spending, where over 50 cents of every dollar goes to intermediaries.
• ⚖️ The company supports efforts to equalize negotiation periods for small molecules and biologics, as well as addressing the 340B drug pricing program.
• 🇨🇳 Tariffs are expected to have a nominal impact, but Merck is focused on resilient, US-based manufacturing to mitigate long-term risks and align with policies aimed at reducing dependence on China.

Global Supply Chain and Security

• 🌍 Merck is working to create a risk-mitigated, resilient supply chain by moving production for the US market to the United States, while continuing to serve other global markets from existing sites.
• 🛡️ This strategy enhances national security by ensuring a secure drug supply for US patients, regardless of global situations.